Michael Murninkas
Overview
Explore the profile of Michael Murninkas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berman N, Pozailov S, Krymko H, Slanovic L, Murninkas M, Grunseid M, et al.
Pediatr Res
. 2025 Jan;
PMID: 39821132
Background: Coarctation of the aorta (CoA) is a narrowing of the aorta that affects 5-8% of congenital heart defects. Treatment options include surgical repair or transcatheter management with endovascular stenting...
2.
Burg S, Levi O, Elyagon S, Shapiro S, Murninkas M, Etzion S, et al.
PNAS Nexus
. 2024 May;
3(5):pgae192.
PMID: 38783894
Atrial fibrillation (AF), the most common cardiac arrhythmia, is strongly associated with several comorbidities including heart failure (HF). AF in general, and specifically in the context of HF, is progressive...
3.
Murninkas M, Gillis R, Elyagon S, Levi O, Mulla W, Katz A, et al.
Am J Physiol Heart Circ Physiol
. 2023 Feb;
324(4):H461-H469.
PMID: 36735403
The utility of rodents for research related to atrial fibrillation (AF) is growing exponentially. However, the obtained arrhythmic waveforms are often mixed with ventricular signals and the ability to analyze...
4.
Mulla W, Murninkas M, Levi O, Etzion Y
Front Physiol
. 2022 Oct;
13:1002203.
PMID: 36304573
QT interval, a surrogate measure for ventricular action potential duration (APD) in the surface ECG, is widely used to identify cardiac abnormalities and drug safety. In humans, cardiac APD and...
5.
Miller J, Ostrovsky D, Murninkas M, Novack V
Eur J Intern Med
. 2022 Sep;
107:120-121.
PMID: 36115798
No abstract available.
6.
Burg S, Shapiro S, Peretz A, Haimov E, Redko B, Yeheskel A, et al.
Proc Natl Acad Sci U S A
. 2022 Aug;
119(34):e2202926119.
PMID: 35969786
The Ca-activated SK4 K channel is gated by Ca-calmodulin (CaM) and is expressed in immune cells, brain, and heart. A cryoelectron microscopy (cryo-EM) structure of the human SK4 K channel...
7.
Lee D, Murninkas M, Elyagon S, Etzion Y, Anderson H
Front Pharmacol
. 2021 May;
12:642398.
PMID: 33967775
Atrial fibrillation (AF) leads to rate-dependent atrial changes collectively defined as atrial remodelling (AR). Shortening of the atrial effective refractory period (AERP) and decreased conduction velocity are among the hallmarks...
8.
Murninkas M, Gillis R, Lee D, Elyagon S, Bhandarkar N, Levi O, et al.
Am J Physiol Heart Circ Physiol
. 2020 Dec;
320(2):H713-H724.
PMID: 33337966
The complex pathophysiology of atrial fibrillation (AF) is governed by multiple risk factors in ways that are still elusive. Basic electrophysiological properties, including atrial effective refractory period (AERP) and conduction...
9.
Klapper-Goldstein H, Verma A, Elyagon S, Gillis R, Murninkas M, Pittala S, et al.
Sci Rep
. 2020 Dec;
10(1):22101.
PMID: 33328613
The voltage-dependent anion channel 1 (VDAC1) is a key player in mitochondrial function. VDAC1 serves as a gatekeeper mediating the fluxes of ions, nucleotides, and other metabolites across the outer...
10.
Klapper-Goldstein H, Murninkas M, Gillis R, Mulla W, Levanon E, Elyagon S, et al.
Sci Rep
. 2020 Jan;
10(1):553.
PMID: 31953473
Atrial fibrillation (AF) is a progressive arrhythmia with underlying mechanisms that are not fully elucidated, partially due to lack of reliable and affordable animal models. Here, we introduce a system...